MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$570,119K
Accounts receivable, net
$139,444K
Prepaid expenses and
other current assets
$44,070K
Inventories
$26,753K
Marketable securities
$17,363K
Total current assets
$797,749K
Equity method
investments
$79,972K
Intangible assets, net
$28,077K
Other assets
$16,712K
Operating lease
right-of-use assets
$8,149K
Property and equipment,
net
$5,366K
Accumulated deficit
-$3,821,194K
Treasury stock, at cost
7,597,172 shares as of...
$323,276K
Total assets
$936,025K
Total bridgebio
stockholders deficit
-$2,086,610K
Additional paid-in capital
$2,057,646K
Common stock, 0.001 par
value 500,000,000...
$202K
Accumulated other
comprehensive income
$12K
Total liabilities,
redeemable convertible...
$936,025K
Total stockholders
deficit
-$2,076,011K
Redeemable convertible
noncontrolling interests
-$570K
Noncontrolling interests
$10,599K
Total liabilities
$3,012,606K
Deferred royalty
obligations, net
$855,030K
2031 notes, 2029
notes, 2027 notes, and...
$740,890K
2031 notes, 2029
notes, 2027 notes, and...
$564,565K
2031 notes, 2029
notes, 2027 notes, and...
$547,015K
Total current
liabilities
$287,971K
Deferred revenue, net of
current portion
$13,080K
Operating lease
liabilities, net of current...
$3,811K
Other long-term
liabilities
$244K
Unamortized debt discount
and issuance costs
$57,797K
Carrying value of
deferred royalty...
$891,388K
Other current
liabilities
$120,222K
Accrued compensation
and benefits
$76,703K
Accrued research and
development liabilities
$41,436K
Accounts payable
$36,228K
Deferred revenue,
current portion
$7,190K
Operating lease
liabilities, current portion
$6,192K
Fair value of
embedded derivative...
$21,439K
Funding Agreement
$21,439K
Back
Back
Balance Sheet
source: myfinsight.com
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)